Multimorbidity and chronic pain Signs and Symptoms
Conditions
Interventions
The primary aim of the ACE-MAP study is to assess the feasibility and acceptability of the proposed study procedures. The secondary aim is to generate preliminary data to understand the impact of ACEs
• Health behaviours, using the General Practice Physical Activity Questionnaire (GPPAQ) and the World Health Organization’s Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST)
• Long-term conditions
• Chronic pain, using the CAPE pain questionnaire (in the final stages of development)
• Adverse childhood experiences, using the CAPE ACE questionnaire (in the final stages of development)
• Medication.
Next will be the completion of physical measurements:
• Weight
• Height
• Quantitative sensory testing (QST) on each hand, including thermal thresholds, mechanical thresholds, vibration thresholds, pressure-pain thresholds, stimulus-response function, and wind-up ratio
• Conditioned pain modulation (CPM) using the dominant hand for the test sti
Sponsors
University of Dundee
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Four groups of participants aged =18 years old are eligible for recruitment: 1. Chronic pain with multimorbidity 1.1. Has =1 of the LTCs listed below 1.2. Has a diagnosis of chronic pain AND/OR has had persistent or recurring pain lasting >3 months 2. Chronic pain without multimorbidity 2.1. Has a diagnosis of chronic pain AND/OR has had persistent or recurring pain lasting >3 months 3. Multimorbidity without chronic pain 3.1 Has =2 of the LTCs listed below 4. Healthy volunteer controls List of long-term conditions (LTCs): Cardiovascular disease: stroke, coronary artery disease, heart failure, peripheral artery disease, heart valve disorders, arrhythmia, venous thromboembolic disease, aneurysm, hypertension (treated and untreated). Metabolic and endocrine disease: diabetes, Addison’s disease, cystic fibrosis, thyroid disorders. Respiratory disease: chronic obstructive pulmonary disease, asthma, bronchiectasis. Neurological disease: Parkinson’s disease, epilepsy, multiple sclerosis, paralysis, transient ischaemic attack, peripheral neuropathy. Cancer: solid organ cancers, haematological cancers, metastatic cancers, melanoma, benign cerebral tumours that cause disability. Mental and behavioural disorder: dementia, schizophrenia, depression, anxiety, bipolar disorder, drug or alcohol misuse, eating disorder, autism, post-traumatic stress disorder. Musculoskeletal disease: connective tissue disease, osteoarthritis, long-term musculoskeletal problems due to injury, osteoporosis, gout. Digestive disease: chronic liver disease, inflammatory bowel disease, chronic pancreatic disease, peptic ulcer. Urogenital disorder: chronic kidney disease, end-stage kidney disease, endometriosis, chronic urinary tract infection. Haematological disorder: anaemia (including pernicious anaemia and sickle cell anaemia). Eye disease: vision impairment that cannot be corrected. Ear disease: a hearing impairment that cannot be corrected, Meniere’s disease. Infectious disease: human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), chronic Lyme disease, tuberculosis, post-acute Covid-19. Congenital disease: congenital disease or chromosomal abnormalities.
Exclusion criteria
Exclusion criteria: 1. Unable to read or speak English to a sufficient standard to complete questionnaires or to follow instructions for sensory tests, 2. Lacks the capacity to consent to participate in the study 3. Chronic pain without multimorbidity: Has =1 of the LTCs 4. Multimorbidity without chronic pain: Has a diagnosis of chronic pain AND/OR has had persistent or recurring pain lasting >3 months 5. Controls: Has =2 of the LTCs; A diagnosis of chronic pain AND/OR has had persistent or recurring pain lasting >3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Recruitment feasibility measured per stream by calculating the overall recruitment rate (number of participants successfully recruited to the study per week) and the recruitment proportion (number of participants successfully recruited to the study divided by the number of potential participants approached) using study records at the end of the study 2. Acceptability measured using a modified version of an acceptability questionnaire administered to study participants at the end of the assessment session. The data will be presented as counts and proportions, with free-text comments presented as either themes or original anonymised quotes. | — |
Secondary
| Measure | Time frame |
|---|---|
| The following outcome variables are collected at the assessment session: 1. Demographics measured using questionnaires 2. Long-term conditions measured using questionnaires 3. Chronic pain measured using the CAPE pain questionnaire 4. Adverse childhood experiences (ACEs) measured using the CAPE ACE questionnaire 5. Medication measured using questionnaires 6. Quantitative sensory testing (QST) on each hand, including thermal thresholds, mechanical thresholds, vibration thresholds, pressure-pain thresholds, stimulus-response function, and wind-up ratio 7. Conditioned pain modulation (CPM) using the dominant hand for the test stimulus (heat pain threshold and pressure pain threshold) and the non-dominant hand for the conditioning stimulus (cold water bath at 10 C) | — |
Countries
Scotland, United Kingdom
Contacts
Public ContactDhaneesha Senaratne
Outcome results
None listed